Las Vegas, Nevada, USA, September 7, 2026
The community-acquired bacterial pneumonia (CABP) treatment market is expected to expand through 2036 amid a substantial disease burden, increasing hospitalization, an aging population, comorbidities and the growing challenge of antimicrobial resistance, according to a newly published market analysis from DelveInsight. The report evaluates current treatment practices, emerging therapies, individual treatment market shares and market forecasts across seven major markets comprising the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. DelveInsight projects positive growth in the CABP treatment market through 2036, while identifying continued innovation in antibacterial therapies as an important factor shaping the future treatment landscape.
Antimicrobial Resistance Drives CABP Treatment Needs
Antimicrobial resistance is emerging as one of the major challenges influencing CABP treatment and pharmaceutical research. DelveInsight notes that resistance among bacterial pathogens can reduce the effectiveness of established antibiotics, increasing the need for therapies with novel mechanisms or complementary approaches. Treatment selection can also depend on local resistance patterns, suspected pathogens, disease severity and individual patient characteristics, making management of bacterial pneumonia increasingly complex. The report estimates that approximately 80% of nearly 4 million community-acquired pneumonia cases in the United States are classified as CABP, highlighting the substantial bacterial disease burden within the broader pneumonia population. Older adults, children and people with underlying medical conditions remain important patient populations because CABP can contribute to significant morbidity, hospitalization and mortality. These factors are expected to sustain demand for effective antibacterial treatment options. The current treatment landscape includes established antibiotics such as omadacycline, delafloxacin and lefamulin, which have expanded therapeutic options for patients who may not respond adequately to conventional treatments. Common antimicrobial approaches include macrolides, beta-lactam combinations, amoxicillin-based regimens, fluoroquinolones and third-generation cephalosporins combined with macrolides. However, the emergence of resistant organisms continues to create an unmet need for additional therapeutic strategies.
Emerging Therapies Could Reshape the CABP Pipeline
DelveInsight identifies several investigational CABP therapies that could influence the market during the forecast period. Among them are CAL02, being developed by Eagle Pharmaceuticals and Combioxin; AON-D21, from APTARION Biotech; and Trimodulin (BT588) from Biotest AG. These candidates represent approaches extending beyond conventional antibiotic treatment and are being investigated for patients with significant disease severity and unmet therapeutic needs. CAL02 is described as a Phase II-stage candidate for severe infections, particularly community-acquired pneumonia in critically ill intensive-care patients. The therapy uses liposomes containing cholesterol and sphingomyelin and is designed to neutralize bacterial virulence effectors, potentially addressing mechanisms involved in organ dysfunction and severe infection. CAL02 has received FDA Fast Track and Qualified Infectious Disease Product (QIDP) designations, according to DelveInsight. These designations are regulatory development incentives and should not be interpreted as evidence of approval or established clinical benefit. Meanwhile, AON-D21 is a Phase II investigational PEGylated aptamer designed to selectively target C5a, an important mediator of inflammatory responses. By modulating the complement pathway, the candidate represents a different therapeutic strategy from conventional antibacterial agents. DelveInsight also identifies Trimodulin and other pipeline candidates as potential contributors to future CABP treatment-market development.
Advertisement
CABP Market Expansion Reflects Therapeutic Innovation
The CABP market forecast for 2026–2036 reflects the interaction between disease prevalence, treatment demand, antimicrobial resistance and pharmaceutical innovation. DelveInsight reports that the United States represented the largest CABP treatment market among the seven major markets in 2025, while ongoing clinical development could introduce additional therapeutic options over the coming decade. The evolving pipeline is particularly important because conventional antibiotic strategies may become increasingly challenged by resistance and treatment failure. New approaches targeting bacterial toxins, virulence factors and host inflammatory pathways could complement antibiotic therapy and potentially broaden options for patients with severe disease. However, the candidates highlighted in the report remain subject to clinical development and regulatory review, and their eventual market impact will depend on clinical efficacy, safety and regulatory outcomes. For the pharmaceutical industry, the CABP landscape therefore represents an important area of anti-infective drug development, particularly as antimicrobial resistance continues to influence global treatment strategies. DelveInsight’s analysis underscores the potential for emerging therapies to reshape the market through 2036, while emphasizing the continuing need for innovative approaches against serious bacterial respiratory infections.
Source: DelveInsight press release
